News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
Cholesterol transport protein emerges as possible target for Parkinson's treatment
Parkinson's disease (PD) is a neurodegenerative condition that causes the progressive loss of dopamine-producing neurons in a brain region called the substantia nigra. Its characteristic symptoms include tremors, slowed movements, rigid muscles and difficulties with balance.
Read at Medical Xpress →Review board improves access to anti-amyloid therapies
SAN DIEGO — As demand increases for anti-amyloid therapy that can slow the progression of Alzheimer’s disease, it will be crucial for healthcare systems to find more efficient ways to review referrals for treatment, according to a presenter. …
Free to read? Not known for this outlet.
Read at Healio →Wireless neural chip tracks brain changes in real time after Alzheimer's drug administration
A joint research team led by KAIST has used a small, implantable neural chip to wirelessly monitor real-time changes in a neurotransmitter involved in memory and learning after an Alzheimer's drug has been administered. …
Read at Medical Xpress →New drug-delivery method offers promise in fight against neurodegenerative diseases
For patients battling neurodegenerative diseases like ALS, Parkinson's, Alzheimer's and other dementias, delivering disease-fighting antibody drugs directly to the brain has proven to be a difficult task. …
Read at Medical Xpress → Archived copy (25 Oct 2026), Internet ArchiveSTAT+: Nobel-winning optogenetics research has led to experimental treatments for blindness and Alzheimer’s
Optogenetics is now the foundational way through which we are able to understand how the brain…
Why it matters: Optogenetics research has led to experimental treatments for blindness and Alzheimer's, serving as a foundational way to understand brain function.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (5 Oct 2026), Internet ArchiveGene editing approach opens potential new route to Alzheimer's treatment
Dr. Kevin Kemp and his research team at the University of Bristol have converted the high-risk Alzheimer's gene APOE4 into the lower-risk APOE3 gene.
Read at Medical Xpress → Archived copy (29 Sep 2026), Internet ArchiveAt-home injection version of Alzheimer’s drug now available in US
In the U.S., people with early Alzheimer’s disease will now have the option for at-home treatment with the approved therapy Leqembi (lecanemab) throughout the entire treatment journey. …
Read at Alzheimer's News Today → Archived copy (2 Oct 2026), Internet ArchiveFDA designation may speed new treatment for Alzheimer’s psychosis
The U.S. Food and Drug Administration (FDA) has granted fast track designation to remlifanserin, an experimental treatment that Acadia Pharmaceuticals is developing for hallucinations and delusions associated with Alzheimer’s disease psychosis. …
Read at Alzheimer's News Today →Lab-grown mini brains may predict which Alzheimer’s treatments will work
Miniature brain models grown from patients’ cells revealed striking differences in how Alzheimer’s-related tissue responds to an antidepressant. …
Read at ScienceDaily → Archived copy (1 Oct 2026), Internet ArchiveCopper drug clears toxic Alzheimer’s proteins and restores memory
A copper-based compound restored the brain’s ability to clear toxic Alzheimer’s proteins, dramatically reducing amyloid buildup and improving memory in laboratory experiments. …
Read at ScienceDaily → Archived copy (20 Sep 2026), Internet ArchiveAlzheimer’s drugs may not work and could raise brain risks
Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually help patients in any meaningful way, according to a major review of over 20,000 participants. …
Daily Alzheimer’s pill slows brain shrinkage, boosts cognition
The benefits seen in people with early Alzheimer’s disease after a year of treatment with blarcamesine (Anavex 2-73) were sustained over nearly three years, according to new analysis from the treatment’s developer, Anavex Life Sciences. …
Read at Alzheimer's News Today → Archived copy (1 Jul 2026), Internet ArchiveHow AI can create a virtual programmable human and revolutionize drug discovery
From idea, to lab, to clinic, to approval—it's a long and expensive process to bring a drug to market. It also rarely succeeds.
Why it matters: AI can create a virtual programmable human and revolutionize drug discovery, which is key because bringing a drug to market is a long, expensive process that rarely succeeds.
Read at Medical Xpress → Archived copy (17 Dec 2025), Internet ArchiveFollow new items in a feed reader: Atom feed.